

1 **Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors**

2
3 Seyed Arad Moghadasi¹, Emmanuel Heilmann^{2,*}, Ahmed Magdy Khalil^{3,4*}, Christina
4 Nnabuike^{5,*}, Fiona L. Kearns^{6,*}, Chengjin Ye³, Sofia N. Moraes¹, Francesco Costacurta², Morgan
5 A. Esler¹, Hideki Aihara¹, Dorothee von Laer², Luis Martinez-Sobrido³, Timothy Palzkill⁵,
6 Rommie E. Amaro⁶ & Reuben S. Harris^{1,7,8,#}

7
8 ¹Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota –
9 Twin Cities, Minneapolis, Minnesota, USA, 55455

10 ²Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria

11 ³Texas Biomedical Research Institute, San Antonio, Texas, USA, 78227

12 ⁴Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Zagazig University,
13 Zagazig, Egypt, 44511

14 ⁵Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston,
15 Texas, USA, 77030

16 ⁶Department of Chemistry and Biochemistry, University of California San Diego, La Jolla,
17 California, USA, 92093

18 ⁷Department of Biochemistry and Structural Biology, University of Texas Health San Antonio;
19 San Antonio, Texas, USA, 78229

20 ⁸Howard Hughes Medical Institute, University of Texas Health San Antonio; San Antonio,
21 Texas, USA, 78229

22 * Equal secondary contributions

23 # Corresponding author. Email: rsh@uthscsa.edu

24
25 **Manuscript Information:** 81 character title, 138 word abstract, 5800 word main text (excluding
26 references and figure legends), Figures 1-5, Tables 1-3, Supplementary Figures S1-S12,
27 Supplementary Tables S1-3

28
29 **Keywords:** antiviral drugs; natural genetic variation; Paxlovid (nirmatrelvir); Xocova
30 (ensitrelvir); protease inhibitor resistance; SARS-CoV-2 main protease (M^{pro}/3CL^{pro})

31
32 **One Sentence Summary:** Resistance to protease inhibitor drugs, nirmatrelvir (Paxlovid) and
33 ensitrelvir (Xocova), exists in SARS-CoV-2 variants in the human population.

34
35 **Abstract:** Vaccines and drugs have helped reduce disease severity and blunt the spread of
36 SARS-CoV-2. However, ongoing virus transmission, continuous evolution, and increasing
37 selective pressures have the potential to yield viral variants capable of resisting these

1 interventions. Here, we investigate the susceptibility of natural variants of the main protease
2 ($M^{\text{pro}}/3\text{CL}^{\text{pro}}$) of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in M^{pro}
3 confer resistance to nirmatrelvir (the active component of Paxlovid). An additional clinical-stage
4 inhibitor, ensitrelvir (Xocova), shows a different resistance mutation profile. Importantly,
5 phylogenetic analyses indicate that several of these resistant variants have pre-existed the
6 introduction of these drugs into the human population and are capable of spreading. These results
7 encourage the monitoring of resistance variants and the development of additional protease
8 inhibitors and other antiviral drugs with different mechanisms of action and resistance profiles
9 for combinatorial therapy.

11 INTRODUCTION

12 The main protease ($M^{\text{pro}}/3\text{CL}^{\text{pro}}$) of coronaviruses (CoV) is an attractive target for drug
13 development, initially pursued in response to the first severe acute respiratory syndrome (SARS)
14 pandemic in 2002 and swiftly revisited in response to the more recent SARS-CoV-2
15 (SARS2)/COVID-19 pandemic (1-4). M^{pro} activity is essential for virus replication and,
16 combined with precedents set by the successful development of human immunodeficiency virus-
17 type 1 (HIV-1) and hepatitis C virus (HCV) protease inhibitors, drugs targeting this enzyme are
18 likely to help treat SARS2 infections (5, 6). Many groups have embarked on campaigns to target
19 M^{pro} with multiple chemical series being advanced into potent inhibitors at unprecedented
20 speeds, mainly owing to the wealth of biochemical and structural information that has
21 accumulated on coronaviruses proteases over the past two decades (7-11). For instance, prior
22 knowledge accelerated the development of PF-00835231 into PF-07321332 (nirmatrelvir), the
23 active ingredient in Paxlovid and the first M^{pro} inhibitor to be used clinically (12). Another M^{pro}
24 inhibitor that recently received emergency use authorization in Japan is S-217622 (ensitrelvir,
25 Xocova), a non-covalent, non-peptidic inhibitor developed through computational and medicinal
26 chemistry (13, 14). Ensitrelvir and other molecules in various stages of development may soon
27 provide alternatives to Paxlovid and present opportunities for combinatorial therapy.

28 While Paxlovid is already proving useful in blunting SARS2 disease pathogenesis, the
29 long-term consequences of wide-spread use are unknown. Resistance is a major concern given
30 the relatively rapid rates at which SARS2 is changing (Alpha, Beta, Delta, Omicron, *etc.*) and the
31 fact that the potency of nirmatrelvir and ensitrelvir varies widely against other coronavirus
32 species (15). For instance, the main proteases of the human α -coronaviruses NL63 and 229E are
33 less susceptible to these drugs suggesting that natural mechanisms of resistance may already
34 exist in nature (12, 16). In addition, during the clinical development of Paxlovid, murine
35 coronavirus MHV-A59 was used to study nirmatrelvir resistance (17). One of the selected amino
36 acid changes, corresponding to S144A in SARS2, causes a >90-fold reduction in the binding
37 efficacy (K_i) of nirmatrelvir to recombinant M^{pro} *in vitro*.

38 We recently reported a cell-based gain-of-signal assay for SARS2 M^{pro} function in which
39 wildtype (WT) protease activity suppresses luminescent signal by cleaving cellular substrates to
40 prevent accumulation of reporter mRNA and, importantly, this suppressive effect can be
41 overcome by genetic or chemical inhibition of M^{pro} to yield signal increases proportional to
42 mutant severity or inhibitor efficacy, respectively (16). This system enabled us to show that
43 single amino acid changes (P168S and P168G) in an active site-adjacent β -hairpin of M^{pro}
44 improve susceptibility to the HCV protease inhibitor boceprevir, yet have no effect on the

1 inhibitory capacity of the tool compound GC376 [(16); repeated below]. P168S is a naturally
2 occurring variant that accounts for 76% of amino acid changes at this position in SARS2 clinical
3 isolates based on sequences deposited in the GISAID database [1-July-2022; (18)]. This example
4 of differential drug responsiveness inspired us to use evolution- and structure-guided approaches
5 here to ask whether this natural variation at position 168, other natural changes at position 168,
6 and other naturally occurring variants in the vicinity of the M^{pro} active site cavity may confer
7 resistance to nirmatrelvir and/or ensitrelvir. Our results combine to demonstrate that multiple
8 drug resistance mutations already exist in transmissible isolates of SARS2 in the global
9 population. However, some M^{pro} variants that show resistance to nirmatrelvir still retain full
10 susceptibility to ensitrelvir and *vice versa*, consistent with distinct mechanisms of action and the
11 possibility that the latter drug can be used if the former fails and *vice versa*.

12

13 RESULTS

14 A natural M^{pro} variation Δ P168 confers resistance to nirmatrelvir and ensitrelvir

15 As introduced above, P168S is the most frequent amino acid change observed at this
16 position in SARS2 M^{pro}. The next most frequent change at this position in the GISAID database
17 is a single residue deletion, Δ P168 (21% of changes at this position on 1-July-2022; **Fig. 1A**;
18 **Table 1**). High resolution structures show that P168 is located close to the binding sites of
19 boceprevir and nirmatrelvir (4.0 Å and 3.3 Å, respectively), and it is approximately twice as far
20 from that of ensitrelvir [8.8 Å; (14, 19)] (**Fig. 1B**). Based on our prior work with the P168S
21 variant (16), we predicted that changes at this amino acid position in M^{pro} would more strongly
22 affect the efficacy of boceprevir and nirmatrelvir and have little effect on ensitrelvir. Using our
23 cell-based gain-of-signal assay (**Fig. S1A**), P168S causes a 5.5-fold increase in susceptibility to
24 boceprevir in confirmation of our prior studies (**Fig. 1C**, left). We were therefore surprised to
25 find that Δ P168 has no detectable effect with boceprevir, as its dose response curve is
26 indistinguishable from that of WT M^{pro}. In contrast, the Δ P168 variant shows 5.1- and 6.8-fold
27 increased resistance to nirmatrelvir and ensitrelvir, respectively, whereas P168S variant
28 maintains WT-like responsiveness to these two drugs (**Fig. 1C**, middle and right; **Table 1**). As a
29 positive control, the S144A mutant described in the Introduction also shows a strong resistance
30 phenotype for both nirmatrelvir and ensitrelvir with 12.2- and 16.9-fold increases in IC₅₀
31 compared to WT M^{pro}, respectively (**Fig. S1B**; **Table 1**).

32 An additional metric of our cell-based assay for M^{pro} function is background luminescent
33 signal in the absence of a protease inhibitor (16). The WT construct yields very low
34 luminescence and any diminution in M^{pro} catalytic activity results in increased signal with a
35 maximum of approximately 40-fold as defined by a catalytic inactivating mutation (C145A, **Fig.**
36 **1D**). Consistent with our previous biochemical work (16), P168S shows no change in
37 background luminescence relative to WT, whereas the genetically selected mutant S144A causes
38 a 3.5-fold increase (**Fig. 1D**), in line with a reported decrease in biochemical activity (20). In
39 comparison, Δ P168 elicits an intermediate, 2-fold increase in background luminescence (**Fig.**
40 **1D**). These results suggest that Δ P168 M^{pro} has near-WT catalytic activity and may be capable of
41 supporting virus replication (addressed directly below). In support of both inhibitor resistance
42 and protease activity results, the increased resistance of the M^{pro} Δ P168 variant to both
43 nirmatrelvir and ensitrelvir is also apparent using an orthogonal VSV-based M^{pro} *cis*-cleavage
44 assay in which inhibition of catalytic activity enables VSV replication (21) (**Fig. 1E**; **Table 2**).

1

2 **Drug resistance profiles of additional naturally occurring single amino acid M^{pro} variants**

3 Encouraged by the resistance phenotypes caused by amino acid changes at a single
4 position, we extended our analyses to include nine additional naturally variable residues that
5 localize to two separate regions in proximity to the M^{pro} active site (**Fig. 2A-B; Table 1**). First,
6 given the strong phenotypes observed with P168 variants, we hypothesized that mutations at
7 additional residues within this β -hairpin might also confer drug resistance. Specifically, residues
8 165, 169, 171, and 173 show variability across coronavirus species (**Fig. 2A**) and, importantly,
9 also within circulating SARS2 variants (**Fig. 2C**). M165, T169, and V171 were each substituted
10 with isoleucine because this is a recurrent change at these positions, and A173 was substituted to
11 valine as the most observed change at this position in SARS2 and also the residue found
12 naturally in the human α -coronaviruses HCoV-229E and -NL63, both of which exhibit decreased
13 susceptibility to nirmatrelvir (12, 16). The second region of interest encompasses M^{pro} residues
14 45-49, a small helix that forms the lid of the hydrophobic S2 subsite through the sidechain of
15 M49. Notably, this is the most variable region across different coronaviruses species both in
16 amino acid identity as well as overall length (**Fig. 2A**). For instance, M49I is a frequent change
17 in circulating viruses (>1000 occurrences) and a substitution we have previously shown to have
18 little effect in GC376 or boceprevir susceptibility (16), but its impact on nirmatrelvir and
19 ensitrelvir efficacy has yet to be analyzed. Furthermore, we were intrigued by the hydrogen
20 bonding pattern formed by T45 and D48 and curious whether naturally occurring changes that
21 disrupt these interactions (T45I and D48Y) might destabilize the helical structure and impact
22 inhibitor binding (**Fig. 2B**). Similarly, S46F and E47K were selected as non-conservative
23 changes that may also disrupt the secondary structure of this region and impact inhibitor
24 responsiveness.

25 Of the nine amino acid substitution mutants described above, five (S46F, E47K, M165I,
26 T169I, and V171I) have little effect (<2-fold) on M^{pro} susceptibility to either nirmatrelvir or
27 ensitrelvir and cause no substantial increases in background luminescence, consistent with near-
28 WT catalytic activity (**Fig. 2D-E; Table 1**). In contrast, A173V immediately stands out as a
29 separation-of-function variant by causing a 11.6-fold increase in resistance to nirmatrelvir and no
30 change in susceptibility to ensitrelvir (**Fig. 2E; Table 1**). Importantly, A173V does not appear to
31 drastically impact protease activity given the modest, 2-fold increase in background
32 luminescence in the absence of inhibitor compared to WT M^{pro} (**Fig. 2D**). Additional contrast is
33 seen with mutations surrounding the S2 subsite. T45I and D48Y cause 4.1- and 5-fold increases
34 in resistance to ensitrelvir relative to the WT, and both have more modest effects on nirmatrelvir
35 susceptibility (approximately 2-fold; **Fig. 2E; Table 1**). Strikingly, M49I causes no shift in the
36 nirmatrelvir dose response in comparison to a 12.4-fold increase in resistance to ensitrelvir (**Fig.**
37 **2E; Table 1**).

38 Given the contrasting effects on inhibitor resistance caused by A173V and M49I,
39 additional amino acid substitutions were generated for these two positions to gain additional
40 insights into resistance mechanisms. A173T and A173S are variants observed in GISAID at
41 frequencies similar to A173V; however, A173S causes no resistance to nirmatrelvir, whereas
42 A173T causes an intermediate 4.1-fold resistance phenotype, suggesting that the bulkiness of the
43 side chain of residue 173 correlates with the magnitude of nirmatrelvir resistance (**Fig. 2F; Table**
44 **1**). Similar to A173V, A173T and A173S do not affect susceptibility to ensitrelvir (**Fig. 2F**).
45 M49V, M49T, and M49L are also found in circulating isolates, but at lower frequencies than

1 M49I (**Table 1**). M49V and M49T cause milder phenotypes with 2.6- and 4-fold resistance to
2 ensitrelvir, respectively (**Fig. 2F**; **Table 1**). In contrast, M49L causes 25.4-fold resistance to
3 ensitrelvir and no change in nirmatrelvir susceptibility (**Fig. 2F**; **Table 1**). Notably, MERS has a
4 leucine at the equivalent position in M^{pro} (**Fig. 2A**), and it exhibits higher ensitrelvir antiviral
5 EC₅₀ values compared to SARS and SARS2 (14). All these additional variants at M49 and A173
6 tested exhibit less than 2-fold changes in background luminescence compared to WT M^{pro}
7 suggesting negligible changes in catalytic activity (**Fig. S2**). All single amino acid changes that
8 exhibit resistance phenotypes using the gain-of-signal assay show similar results with
9 nirmatrelvir and ensitrelvir in an orthogonal VSV-based M^{pro} assay (21) (**Fig. S3**; **Table 2**).

10

11 **A double mutant of M^{pro} with synergistic resistance to nirmatrelvir**

12 Within our panel of naturally occurring single amino acid M^{pro} variants, two of the largest
13 effects on nirmatrelvir resistance are ΔP168 and A173V (5.1- and 11.6-fold, respectively). This
14 prompted us to test whether the combination might be additive or multiplicative in terms of drug
15 resistance. Remarkably, the ΔP168/A173V double mutant shows a 51-fold increase in resistance
16 to nirmatrelvir (**Fig. 3A**; **Table 1**). In contrast, this double mutant elicits only a 2.8-fold increase
17 in resistance to ensitrelvir, which is less than that of the ΔP168 mutant alone (compare response
18 curves in **Fig. 3A** and **Fig. 1C**, and numeric values in **Table 1**). As above, these single mutations
19 have modest effects on background luminescence levels relative to WT, and the double mutant
20 elicits a roughly additive effect with less than 3-fold increase in overall luminescence indicative
21 of protease functionality (**Fig. 3B**). The VSV-based system yields similar resistance phenotypes
22 for the single and double mutants (**Table 2**). These results combine to suggest that a strong
23 resistance to nirmatrelvir can be achieved by combining two naturally occurring amino acid
24 changes.

25 To directly characterize the biochemical properties of these mutants, recombinant M^{pro}
26 was purified from *E. coli* with an N-terminal SUMO-tag and a C-terminal His-tag, which are
27 removed during purification to generate enzymes with authentic N- and C-termini (22). The WT,
28 A173V, and ΔP168/A173V enzymes purify to near homogeneity but, despite multiple attempts,
29 the ΔP168 single mutant was not amenable to purification [precise reason(s) unclear but
30 potentially due to poor solubility and/or aggregation propensity in bacteria]. Michaelis-Menten
31 kinetics for WT M^{pro} hydrolysis of a FRET peptide Dabcyl-KTSAVLQSGFRKM-E(Edans)-NH₂
32 yield a k_{cat} of 0.43 s⁻¹ and k_{cat}/K_M of 7.5 x 10³ M⁻¹s⁻¹, consistent with prior values (23, 24) (**Fig.**
33 **3C**; **Fig. S4A**). The A173V substitution causes a 3-fold increase in k_{cat} and a less than 2-fold
34 decrease in k_{cat}/K_M (**Fig 3C**; **Fig. S4A**). The ΔP168/A173V enzyme also displays near-WT
35 kinetic parameters with a 2-fold increased k_{cat} and a less than 2-fold decrease in k_{cat}/K_M (**Fig. 3C**;
36 **Fig. S4A**). These results indicate that neither the A173V nor the ΔP168/A173V enzyme exhibits
37 a major decline in M^{pro} catalytic activity.

38 The same FRET-based system was then used to quantify inhibition by nirmatrelvir and
39 ensitrelvir. WT M^{pro} is inhibited potently by nirmatrelvir with a K_i of 1.1 ± 0.95 nM, again
40 consistent with prior values (12) (**Fig. 3D**; **Fig. S4B**). In contrast, nirmatrelvir is 50-fold less
41 potent against A173V M^{pro} with a K_i of 57 ± 4.2 nM (**Fig. 3D**; **Fig. S4B**). Strikingly, nirmatrelvir
42 is nearly 600-fold less potent against the ΔP168/A173V enzyme with a K_i value of 590 ± 74 nM
43 (**Fig. 3D**; **Fig. S4B**). In comparison, ensitrelvir inhibits WT and A173V enzymes similarly with
44 K_i values of 0.2 ± 0.56 nM and 2.3 ± 0.94 nM (p value = 0.19 by unpaired t -test). The K_i of

1 ensitrelvir for the double mutant is higher (23 ± 4.1 nM) and, by deduction, this is likely due to
2 Δ P168. These biochemical findings agree with results from the two live cell assays described
3 above and collectively indicate that the A173V and Δ P168/A173V enzymes are active and that
4 these naturally occurring amino acid changes confer a strong and preferential resistance to
5 nirmatrelvir.

6 As an additional functional test, we built these resistance mutants of M^{pro} into a bacterial
7 artificial chromosome (BAC)-based reverse genetics system (WA-1 strain), produced viral
8 stocks using Vero-E6 cells, and performed a series of drug titration experiments as described
9 (25). This system has an mCherry reporter linked to the viral N-gene and separated at the
10 translation level by a 2A self-cleavage site, enabling quantification of virus infectivity and
11 replication by fluorescence microscopy (25) (**Fig. S5A**). To determine drug susceptibility, A549-
12 hACE2 cells were infected with virus encoding WT, Δ P168, A173V, or Δ P168/A173V M^{pro} at
13 equal multiplicities of infection, then treated with varying concentrations of antiviral inhibitors,
14 and virus replication was quantified 72 hours post-infection (hpi) by analyzing mCherry
15 fluorescence. Whereas the virus encoding Δ P168 M^{pro} does not exhibit resistance to nirmatrelvir,
16 A173V M^{pro} causes an 8.1-fold increase in EC₅₀ and, strikingly, Δ P168 synergizes with A173V
17 to cause a 62.5-fold increase in EC₅₀ (**Fig. 3E-G**; **Fig. S5B**; **Table 3**). In contrast, none of these
18 mutants alter virus susceptibility to ensitrelvir, which suggests that the level of resistance caused
19 by Δ P168 alone in cell-based assays M^{pro} inhibition assays is insufficient to alter susceptibility in
20 a viral context. Importantly, these results indicate that the Δ P168/A173V double mutant virus is
21 still inhibited effectively by ensitrelvir, despite a strong resistance to nirmatrelvir (**Fig. 3E-F**). As
22 expected, none of the mutants alter susceptibility to remdesivir, which acts by inhibiting the viral
23 RNA dependent RNA polymerase (**Fig. 3E-F**). Surprisingly, whereas the Δ P168 virus shows
24 WT-like replication kinetics, the A173V virus exhibits a spreading replication defect which
25 remained unaltered when combined with Δ P168 (**Fig. S5C**). Although the catalytic efficiency of
26 the A173V mutant is similar to the WT enzyme using a model substrate *in vitro* that mimics the
27 Nsp4-5 cleavage site (above), it is possible that one or more natural cleavage sites in the viral
28 polyprotein may be disproportionately affected by this change during authentic virus replication.

29

30 **Possible structural explanations for key resistance phenotypes**

31 To determine a structural basis for the differential resistance to nirmatrelvir and
32 ensitrelvir, we performed molecular dynamics (MD) simulations and calculated root-mean
33 square fluctuations (RMSF) to estimate per-residue perturbations related to Δ P168 and A173V.
34 First, RMSF analyses of WT and variant M^{pro} enzymes trajectories indicate two regions of high
35 flexibility – residues 40-65 and 185-195. Interestingly, the former region shows increased
36 flexibility attributable to Δ P168 and A173V, whereas the latter region – like the rest of the
37 protein – shows similar mobility regardless of variation (**Fig. 4A**; **Fig. S6**). Residues 40-65
38 comprise two α -helices that form a lid-like motif immediately above the S2 subsite of M^{pro} (top
39 left in **Fig. 4B**). A partially unfolded state in the Δ P168 variant is observed for the α -helix
40 directly adjacent to catalytic histidine (residues 43-53; top right in **Fig. 4B**), and this is
41 exacerbated for the A173V and Δ P168/A173V variants where this region is frequently seen fully
42 unfolded (bottom left and right, respectively, in **Fig. 4B**). Such open conformations may
43 decrease capacity of M^{pro} for native substrate recognition and account for the higher observed K_M
44 values (**Fig. S4**).

1 In contrast, “closed” conformations of the same loop region may impart nirmatrelvir
2 resistance. With A173V and Δ P168/A173V, the 43-53 loop encroaches upon the S4 subsite, a
3 hydrophobic sub-pocket required for binding native substrates and the trifluoroacetamide moiety
4 of nirmatrelvir (**Fig. 4B-C; Fig. S7A-C**). This is evidenced by increased variability in the
5 distance between M49 and the S4 subsite (**Fig. 4C**). The closing of this loop region may also
6 tighten the S2 subsite and clash with the fused cyclopropyl ring at the P2 position of nirmatrelvir
7 (**Fig. 4B**). In comparison, ensitrelvir does not occupy either the S4 or S2 subsite and instead
8 projects outwards into the S1' subsite, which is consistent with our finding that A173V has little
9 effect on the efficacy of ensitrelvir (**Fig. S7D**).

10 MD simulations also indicate that Δ P168 may negatively impact L167-G170 backbone
11 H-bonding regardless of the residue (A or V) at position 173 (**Fig. 4D-E, Fig. S8**). The 165-175
12 β -hairpin sits above the interdomain loop (IDL, residues 180-200) to form the S3/4 subsite, and
13 loss of this hydrogen bond has the potential to destabilize the hairpin structure. Notably, inward
14 motion of the IDL is restricted by positioning of the 165-175 β -hairpin which is consistent with
15 increased flexibility in the Δ P168 mutant (**Fig. 4A**). Whereas IDL structure modulates inhibitor
16 binding, destabilization of the hairpin allows its encroachment into the S4 sub-pocket thereby
17 decreasing inhibitor potency.

18 19 **Insights from additional double mutant combinations**

20 Given the synergistic effect of Δ P168 and A173V on nirmatrelvir resistance, we next
21 used our gain-of-signal cell-based assay to investigate double mutant combinations involving
22 residues in the lid region described above (*i.e.*, residues 40-70; **Fig. S9A-B; Table 1**). First, we
23 combined the ensitrelvir resistant mutant T45I with single amino acid changes that confer
24 resistance to ensitrelvir (M49L), nirmatrelvir (A173V), or both drugs (Δ P168). The T45I/M49L
25 combination shows a synergistic 54.5-fold increase in ensitrelvir resistance, little change in
26 susceptibility to nirmatrelvir, and no increase in background luminescence. The T45I/A173V
27 combination exhibits a 20.6-fold increase in resistance to nirmatrelvir (more than additive), a
28 4.2-fold increase in resistance to ensitrelvir (near identical to T45I alone), and a modest 2-fold
29 increase in background luminescence (similar to A173V alone). The effect of the T45I/ Δ P168
30 combination could not be assessed accurately for drug resistance because it likely attenuates
31 inferred M^{pro} catalytic activity as indicated by a >10-fold increase in background luminescence.
32 This result is unexpected given that T45I and Δ P168 alone only modestly elevate background
33 luminescence and suggests that this double mutant will not be infectious. Key double mutant
34 results are recapitulated in the VSV-based M^{pro} cleavage assay (**Fig. S9C; Table 2**).

35 We also examined two double mutant combinations involving M49I, a mutation that
36 alone confers 12-fold resistance to ensitrelvir and no change to nirmatrelvir (**Fig. S9A-B; Table**
37 **1**). M49I/ Δ P168 and M49L/ Δ P168 combinations confer a synergistic resistance to ensitrelvir of
38 52- and 127-fold, respectively, whereas resistance to nirmatrelvir is only approximately 7-fold
39 for both double mutants (similar to Δ P168 alone). With regards to inferred catalytic activity,
40 M49I/ Δ P168 shows background luminescence indistinguishable from WT and M49L/ Δ P168 has
41 a 3.7-fold increase. These results highlight how even subtle changes in amino acid side chains
42 can have significant effects on inhibitor resistance and/or enzyme catalysis. M49L double
43 mutants were not tested in the VSV-based M^{pro} cleavage assay because this substitution alone
44 already confers near-complete resistance to ensitrelvir (**Fig. S3; Table 1**).

1

2 **Global SARS2 variant distributions and evidence for transmission**

3 The global frequency and distribution of an individual mutant indicates whether a
4 particular amino acid change might be tolerated in nature. However, the current large sequence
5 volume of SARS2 genomes in the GISAID database coupled with low/no stringency filtering
6 results in the identification of mutations at every position of M^{pro}, even at codons encoding
7 conserved catalytic residues (**Fig. S10A**). This strongly suggests that the database contains a
8 certain level of sequences that are not viable and therefore not transmitting through the human
9 population. To address this issue, we used Ultrafast Sample placement on Existing tRee
10 (USHER) to determine phylogenetic relationships between genomes harboring drug resistance
11 mutations in M^{pro} (26). Importantly, analyzing mutational distances to common ancestors allows
12 us to identify viral genomes that are hypermutated, such as a genome deposited recently in
13 GISAID with >100 mutations relative to its closest ancestor, including M^{pro} C145A, which is
14 likely a consequence of poor sequence coverage and annotation across the M^{pro} encoding region
15 (**Fig. S10B-C**).

16 In comparison, viral genomes containing Δ P168 have arisen multiple times
17 independently, with the majority occurring in the Delta lineage (**Fig. 5A**). Moreover, a distinct
18 cluster of 49 genomes deposited between September and December of 2021 is derived from a
19 single founder event followed by multiple regional transmissions in Germany, in addition to
20 evidence consistent with spread to England, USA, Austria, and Romania (**Fig. 5B; Fig. S11**).
21 Despite many independent occurrences of Δ P168 in prior lineages, only a single case has been
22 documented in Omicron, identified in the Netherlands in November 2022 (**Fig. 5A**). This bias
23 may result from the fact that all descendants of Omicron carry a characteristic P132H mutation
24 in M^{pro} which might be functionally incompatible with Δ P168. In contrast, M49I and A173V
25 have both occurred multiple times independently since the emergence of Omicron, with
26 phylogenetic clusters indicative of transmission (**Fig. S11**). Overall, there is a higher frequency
27 of M49I than M49L, which may reflect better relative fitness or simply be a consequence of the
28 fact that three different single base substitutions can lead to an isoleucine codon and only two to
29 a leucine (**Fig. 5C**). Moreover, similar to Δ P168, there is only a single introduction of M49L
30 since the emergence of Omicron, which led to 4-related cases in Japan in early 2022 (**Fig. S11**).
31 It is worth noting that these cases of M49L are of the BA 1.1.2 lineage which originated in Japan
32 and contain an additional T169S change in M^{pro}, which may provide a genetic background more
33 tolerant to M49L or may constitute a compensatory mutation (**Fig. S11**).

34 Given these apparent differences in the frequency of certain M^{pro} mutants since the
35 emergence of Omicron, we asked whether the resistant phenotypes observed for M49I, M49L,
36 Δ P168, and A173V could be recapitulated when combined with the P132H change in Omicron
37 M^{pro}. Using the live cell gain-of-signal assay, we observed that the P132H mutation alone causes
38 a 2-fold increase in background luminescence relative to the ancestral WT sequence (**Fig. 5D**),
39 which may be related to a decreased stability reported for this mutant enzyme *in vitro* (25). In
40 combination with P132H, M49I and M49L do not cause additional increases in background
41 luminescence, whereas Δ P168 and A173V both have an additional effect with the former being
42 the most compromised (**Fig. 5D**). These results are consistent with phylogenetic observations
43 above that P132H and Δ P168 may be functionally incompatible. However, most importantly, all
44 mutants show similar drug resistance phenotypes when combined with P132H in our gain-of-
45 signal assay, suggesting that these mutations are capable of conferring resistance to protease

1 inhibitors in the context of currently circulating Omicron variants (**Fig. 5E**).

2

3 **DISCUSSION**

4 Major efforts continue for developing antiviral drugs to complement vaccination-based
5 strategies for treating patients infected by SARS2 with the ultimate hopes of ending the COVID-
6 19 pandemic and fortifying against future coronavirus outbreaks. M^{pro} inhibitors are at the
7 forefront of coronavirus antiviral drug development with Paxlovid (nirmatrelvir) already
8 authorized for emergency clinical use in over 65 countries and several other compounds
9 including ensitrelvir in various stages of development (27). However, drug resistance mutations
10 have the potential to rapidly undermine these therapies. Here, we show that several naturally
11 occurring M^{pro} variants already exhibit resistance to nirmatrelvir and ensitrelvir (results
12 summarized in **Table 1** and **Table 2**). The highest levels of resistance resulting from a single
13 amino acid substitution identified here is A173V for nirmatrelvir (11.6-fold) and M49L for
14 ensitrelvir (25.4-fold). Phylogenetic analyses show that these (and other) variants have arisen
15 multiple times independently in different parts of the globe with regional clusters and genetic
16 linkage providing compelling evidence for transmission.

17 Nirmatrelvir is a substrate-mimicking covalent drug and ensitrelvir is a non-peptide/non-
18 covalent inhibitor (12, 14). Consistent with distinct mechanisms of action, our studies indicate
19 that these inhibitors are subject to at least partly non-overlapping resistance profiles. For
20 instance, A173V confers selective resistance to nirmatrelvir, whereas M49I and M49L confer
21 increased resistance to ensitrelvir. In comparison, Δ P168 appears to have a more broad-spectrum
22 resistance phenotype. Encouragingly, antiviral assays with recombinant SARS2 corroborate our
23 findings with two different cell-based assays and indicate that the Δ P168/A173V virus causes
24 strong resistance to nirmatrelvir with little change in ensitrelvir susceptibility. Variation at
25 additional residues may also produce distinct resistance patterns when present in isolation versus
26 in combination. For instance, T45I and D48Y exhibit a mild preferential resistance to ensitrelvir
27 as single changes; however, when combined with Δ P168, D48Y shows strong resistance to both
28 inhibitors and T45I cripples enzyme activity. Although our structural modeling and MD
29 simulations provide plausible explanations for the A173V (+/- Δ P168) resistance phenotype,
30 additional dedicated studies will be needed to establish other mechanisms of action.

31 During revision of this manuscript, multiple preprints reported M^{pro} mutants with
32 resistance to nirmatrelvir (28-32). A173V was selected during serial passage experiments in the
33 presence of boceprevir and independently in the presence of nirmatrelvir, which coupled with
34 our results suggest that A173 may be a resistance hot spot (29, 30). Our biochemical data using
35 the purified A173V mutant demonstrate a lower affinity for nirmatrelvir as evidenced by a 50-
36 fold increase in K_i with little change in catalytic efficiency against the canonical Nsp4-5 cleavage
37 site. While these results support the selection of these mutants in serial passage, there appears to
38 be some discrepancy in the magnitude of resistance between changes in *in vitro* K_i compared to
39 changes in antiviral EC₅₀. This is observed for other M^{pro} variants such as S144A, which is
40 selected in serial passage and has been determined by Pfizer as causing a 90-fold increase in
41 nirmatrelvir K_i while antiviral studies show a more modest 2-fold increase in antiviral EC₅₀ (30).
42 The smaller changes in antiviral EC₅₀ may result from the fact that M^{pro} has a wide range of
43 affinities (K_d measurements ranging from 28 μ M to 2.7 mM) for its different polyprotein
44 cleavage sites (33). Therefore, while inhibitor affinity may be reduced by these mutants it could

1 still be sufficient to bind the enzyme before cleavage of the lower affinity viral substrates.
2 Therefore, resistance mutations may need to confer K_i increases of multiple orders of magnitude
3 to cause large shifts in antiviral EC_{50} . This interpretation is supported by our results with the
4 $\Delta P168$ mutant, which alone does not confer a shift in antiviral EC_{50} , however $\Delta P168/A173V$ has
5 7.6-fold increase in EC_{50} compared to A173V alone (62.5-fold compared to WT). Our data with
6 these select mutants are concordant across four orthologous assays (two live cell assays, *in vitro*
7 biochemistry, and *in cellulo* with replication-competent virus) suggesting that multiple mutations
8 may be necessary to decrease drug binding affinity and cause resistance.

9 Consistent with our gain-of-signal assay showing only a 2-fold increase in background
10 luminescence, our kinetic analyses of the purified A173V mutant indicate similar catalytic
11 efficiency to WT (<2-fold change in k_{cat}/K_M). However, the multicycle growth kinetic assays
12 with recombinant SARS2 show decreased replication. Independent studies have reported no
13 change in replication kinetics for A173V, whereas another saw a decrease similar to ours that
14 could be rescued by an additional L50F mutation (29, 30). The reason for this discrepancy
15 between replicative fitness of A173V from different labs is currently unclear, but different
16 measurements of quantifying viral replication could be a contributing factor. Although activity is
17 retained on the canonical Nsp4-5 substrate that is a standard for *in vitro* experiments, other
18 cleavage sites along the polyprotein may be disproportionately impacted by this change. For
19 instance, our MD simulations show an increase in the dynamics of amino acids 40-65, which
20 form the top of the S2 subsite that accommodates the hydrophobic P2 position of the peptide
21 substrate. As most cleavage sites along the viral polyprotein have a leucine at P2, phenylalanine
22 and valine are also found at Nsp5-6 and Nsp6-7 junctions, respectively, which may be less
23 efficiently processed by the A173V mutant. Importantly, however, this variant has sufficient
24 activity for virus replication and is observed recurrently in patient sequences and, therefore, it
25 has the potential to contribute to clinical resistance phenotypes.

26 Although many groups have focused appropriately on resistance to nirmatrelvir given its
27 early emergency use authorization by the FDA, ensitrelvir resistance is now equally important to
28 understand given that emergency use authorization was granted in Japan on 22-November-2022.
29 Along with this approval, documentation was released on serial passage experiments selecting
30 for D48G, M49L, P52S, and S144A as resistance mutations (34). These results support our
31 finding of M49L showing the largest resistance phenotype using the gain-of-signal assay and the
32 VSV-based assay. Furthermore, the selection of D48G also substantiates our hypothesis that
33 disrupting hydrogen bonds between T45 and D48 to destabilize the structure of the helix above
34 the S2 subsite can contribute to ensitrelvir resistance (indicated by our data for T45I and D48Y).
35 Another recent report has also identified M49I as conferring selective resistance to ensitrelvir
36 and elegantly demonstrates the structural basis of this phenotype being due to the bulky
37 isoleucine reorienting H41 and disrupting a base stacking interaction with the inhibitor (35). This
38 is consistent with our finding that M49L causes greater resistance than M49I due to branching of
39 the leucine sidechain at the gamma carbon which is closer to H41. Together, these findings
40 indicate that the 45-49 region of M^{PTO} has the potential to become a hotspot for the development
41 of ensitrelvir resistance mutations.

42 By using our facile live cell gain-of-signal assay coupled with sequence- and structure-
43 informed mutation identification, we have been able to identify multiple changes in M^{PTO} that
44 confer varying degrees of resistance to nirmatrelvir and/or ensitrelvir. The resistance phenotypes
45 described here are consistent between the four different assays we have implemented, and they

1 are also consistent with reports by other groups through serial passage of virus or *in vitro*
2 biochemical assays. Our cell-based gain-of-signal assay has the advantage of only requiring the
3 transfection of a single plasmid, which increases the throughput of variant testing compared to
4 generation of recombinant virus or purification of mutant enzymes (especially those that are
5 difficult to purify such as the Δ P168 mutant). Using variants found within patient sequences at
6 residues that are not strictly conserved across coronavirus species has helped identify changes
7 more likely to be compatible with productive viral infection. However, it is important to take
8 great care when classifying variants within the GISAID database as many annotated variants are
9 likely to be sequence artefacts. For example, we found >4000 sequences with a M165Y change,
10 and manual inspection revealed that this is due to a single guanosine deletion in a poly-U stretch,
11 which causes a frameshift after F160 and leads simultaneously to “detection” of H163W, E166Q,
12 and a downstream stop codon (**Fig. S12A-B**). Most of these sequences were produced using
13 long-read nanopore technology which has a 76-fold higher rate of indel errors compared to short-
14 read technology (36). These sequencing and mis-annotation mistakes can lead to incorrect
15 conclusions regarding the presence of variants in the population and therefore manual inspection
16 of viral genomes is encouraged for putative changes at strictly conserved residues or those
17 requiring multiple base changes (28). Determining the phylogenetic relationships of different
18 variants using publicly available tools such as UShER also provides additional validation of the
19 emergence of these variants by identifying common ancestors and dynastic relationships within
20 distinct geographic regions (26).

21 Although our gain-of-signal system provides robust metrics for evaluating mutants and
22 M^{pro} inhibitors in live cells, there are also a few limitations. For instance, although the relative
23 background luminescence can serve as a proxy for catalytic activity, it is currently unclear which
24 cellular substrates are being cleaved to cause low reporter expression, thereby limiting the
25 correlations that may be made to activity of M^{pro} against individual viral polyprotein cleavage
26 sites. Moreover, our current approach focuses on amino acid residues that are variable (and not
27 completely conserved) to avoid changes that would be severely deleterious which limits the
28 potential number of resistance pathways tested. For instance, it is difficult to predict secondary
29 suppressor mutations that could restore fitness of a resistant but deleterious mutation. An
30 example of this is the identification of E166V and E166A selected during serial passage to
31 confer a high level of resistance against nirmatrelvir and other peptidomimetic inhibitors (29-31).
32 As E166 is a highly conserved residue, it was not tested here. Indeed, severe replication defects
33 are evident with single substitutions at E166 but secondary mutations such as L50F and T21I
34 appear to restore fitness (29-31). Thus, the gain-of-signal assay should be considered a valuable
35 tool to study resistance mutations and complement traditional approaches such as serial
36 passaging and competition studies to triage variants of interest that may be selected in cell
37 culture or emerge *in vivo* during patient treatment before proceeding with more experimentally
38 demanding approaches such as protein biochemistry and/or BSL3 testing with infectious viruses.
39 Furthermore, we anticipate that the panel of mutants described here will be able to serve as an
40 asset during the development of future generation M^{pro} inhibitors for rapid resistance profiling in
41 parallel with structure activity relationship studies.

42 It is presently unclear what magnitude of resistance will be necessary for treatment
43 failure in a clinical setting. Precedents with HCV NS3/4A show that single amino acid changes
44 can elicit selective resistance of multiple orders of magnitude towards different inhibitors with
45 minimal impact on viral fitness (37). However, resistance to HIV protease inhibitors often
46 requires two or more mutations, with single amino acid changes typically showing modest

1 changes in inhibitor susceptibility (38, 39). The naturally occurring SARS2 M^{pro} variants
2 described here may serve as evolutionary stepping-stones for intermediate levels of resistance
3 and provide a permissive environment enabling selection of secondary mutations that confer full
4 drug resistance. Genetic surveillance of several of the variants identified here may be
5 advantageous and strategies should be taken to minimize the widespread development of
6 resistance including the careful design of M^{pro} inhibitor drugs with different resistance profiles,
7 which encouragingly is likely to be the case for nirmatrelvir and ensitrelvir.

8 9 **MATERIALS AND METHODS**

10 11 **Cell culture and M^{pro} reporter assays**

12 The pcDNA5/TO-Src-M^{pro}-Tat-fLuc reporter construct has been described (16). M^{pro}
13 variants were generated by site-directed mutagenesis (primers available upon request), and all
14 mutations were confirmed by Sanger sequencing. 293T cells were maintained at 37°C and 5%
15 CO₂ in DMEM (Gibco catalog number 11875093) supplemented with 10% fetal bovine serum
16 (ThermoFisher catalog number 11965084) and penicillin-streptomycin (Gibco catalog number
17 15140122). For each M^{pro} variant, 3x10⁶ 293T cells were plated in a 10cm dish and transfected
18 24h later with 2μg of the corresponding Src-M^{pro}-Tat-fLuc plasmid using TransIT-LT1 (Mirus
19 catalog number MIR 2304) transfection reagent. 4h post transfection, cells were washed once
20 with phosphate buffered saline (PBS), trypsinized, resuspended in fresh media, counted, and
21 subsequently diluted to a final concentration of 4x10⁵ cells/ml. Dilution series of inhibitors were
22 prepared in fresh media at twice the final desired concentration of the reaction and 50μL was
23 pipetted into a 96 well cell culture plate. 50μL of the cell suspension was added directly to the 96
24 well plate with inhibitor containing media to yield a final cell concentration of 20,000 cells per
25 well. 44h after plating into 96 well plates, media was removed and 50μL of Bright-Glo reagent
26 was added to each well and incubated at room temperature in the dark for 5m before transferring
27 to white flat 96-well plate for measuring luminescence on a Biotek Synergy H1 plate reader.
28 Percent inhibition at each concentration of inhibitor was derived with the formula below using
29 the relative luminescence (RL) of an inhibitor treated sample to the untreated control.

$$\% \text{ inhibition} = \%100 - (100 / (RL))$$

30 Results were plotted using GraphPad Prism 9 and fit using a four-parameter non-linear
31 regression to calculate IC₅₀. Resistance of mutants was calculated by the fold change in IC₅₀ of
32 the mutant relative to WT M^{pro}.

33 The *cis*-cleaving VSV based M^{pro} assay was performed as described (21). Briefly, 293T
34 cells were transfected with the phosphoprotein (P)-M^{pro} fusion construct for each variant of
35 interest and after an overnight incubation, resuspended and plated into 96 well plates.
36 Transfected cells were then treated with the intended inhibitor and infected with VSV-ΔP-RFP at
37 an MOI of 0.1. 48h post-infection, fluorescence was measured using a Fluoro/ImmunoSpot
38 counter (CTL Europe GmbH, Bonn, Germany). Data were plotted as relative fluorescence using
39 GraphPad Prism 9 and fit using a four-parameter non-linear regression to calculate IC₅₀.

40 41 **Protein expression and purification**

42 SARS2 M^{pro} and mutants were expressed and purified from *E. coli* BL21(DE3) using a
43 pSUMO-SARS2-M^{pro} protein expression plasmid and purification protocol described previously
44 with minor variations (22). Briefly, M^{pro}, A173V, and ΔP168/A173V mutants were expressed
45 with an N-terminal SUMO-tag and a C-terminal His-tag. The M^{pro} open reading frame sequence

1 was flanked on the N terminus by its endogenous cleavage site (SAVLQ↓SGFRK) and on its C
2 terminus by a PreScission protease cleavage site (SGVTFQ↓GP). The N-terminal SUMO tag
3 was cleaved by M^{pro} during protein expression in *E. coli*. Cells containing the pSUMO-SARS2-
4 M^{pro} plasmid were grown in Luria broth (LB) at 37°C to an optical density 600 nm of 0.8 to 1
5 and M^{pro} expression was induced with 0.4 mM isopropyl β-D-1-thiogalactopyranoside for 20 hrs
6 at 20°C. Cells were harvested by centrifugation and resuspended in binding buffer [25 mM
7 Tris·HCl pH = 8.0, 150 mM NaCl, 5 mM β-mercaptoethanol, 20 mM imidazole, and Xpert
8 protease inhibitor mixture (GenDEPOT)]. Cells were disrupted by sonication and cell debris
9 were removed by centrifugation. The supernatant was loaded onto a Ni²⁺ Sepharose 6 Fast Flow
10 column. After washing, protein was eluted by adding buffer A (25 mM Tris·HCl, pH 8.0, 150
11 mM NaCl, 5 mM β-mercaptoethanol, and Xpert protease inhibitor mixture) supplemented with
12 40, 60, 80, and 100 mM imidazole, respectively. Fractions containing M^{pro} based on SDS-PAGE
13 were pooled and buffer-exchanged with buffer B [20 mM Tris·HCl, pH 7.3, 150 mM NaCl, 1
14 mM EDTA and 1 mM dithiothreitol (DTT)] using a Amicon Ultra-15 Centrifugal Filter Unit
15 (Millipore Sigma). The sample was treated with PreScission protease to remove the His-tag and
16 create an authentic M^{pro} C-terminus. The sample was then applied to a Ni²⁺ Sepharose 6 Fast
17 Flow resin was applied to the protein solution to remove remaining M^{pro}-His. M^{pro} was then
18 concentrated and applied to a Superdex 75 Increase 10/300GL size-exclusion column (GE
19 Healthcare) preequilibrated with buffer B. Fractions containing M^{pro} were assessed by SDS-
20 PAGE and pooled for further use.

21

22 **Enzyme kinetics and inhibition assays *in vitro***

23 To determine Michaelis-Menten kinetic parameters we utilized a fluorescent peptide,
24 DabcyI-KTSAVLQSGFRKM-E(Edans)-NH₂, as a FRET substrate with an excitation
25 wavelength of 360 nm and emission wavelength of 460 nm as described (22). We first
26 determined the inner filter effect associated with the peptide and hydrolysis. This was done by
27 measuring the fluorescence of the FRET peptide at 0, 7.5, 15, 30, 60, 90, and 120 μM and also at
28 these peptide concentrations in the presence of 0.5 μM free EDANS. The difference in
29 fluorescence with and without EDANS was used to calculate an inner filter effect correction as
30 described (40). Fluorescence units were converted to hydrolysis product concentration in μM by
31 running the M^{pro} hydrolysis reaction to completion for 0.5, 1, 5, 10, and 15 μM of FRET peptide
32 and determining the change in fluorescence for the reaction, after inner filter effect correction.
33 The change in fluorescence for the complete reaction was plotted versus peptide concentration to
34 create a standard curve to convert fluorescence units to mM peptide hydrolyzed.

35 The Michaelis-Menten kinetic parameters k_{cat} , K_M and k_{cat}/K_M were determined for M^{pro}
36 and mutant derivatives by measuring the initial velocity of peptide hydrolysis as indicated by the
37 change in fluorescence and converted to μM. An inner filter effect correction was determined for
38 each peptide concentration used and was applied to determine the initial velocity. The reactions
39 were performed in 20 mM Tris·Cl pH 7.3, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.02%
40 Tween-20. The initial velocities were plotted versus peptide concentration and fit to the
41 Michaelis-Menten equation:

$$(V_{max} * S) / (K_M + S)$$

42 with $k_{cat} = V_{max}/E_0$, where E_0 is the enzyme concentration used.

43 The potency of the PF07321332 and S217622 compounds for inhibition of M^{pro} and the
44 A173V and ΔP168/A173V enzymes was evaluated using hydrolysis of the DabcyI-
45 KTSAVLQSGFRKM-E(Edans)-NH₂ FRET peptide described above as a reporter. The

1 inhibition assays were performed in 20 mM Tris-Cl pH 7.3, 100 mM NaCl, 1 mM EDTA, 1 mM
2 DTT, and 0.02% Tween-20. The reporter peptide was used at 15 μ M with increasing
3 concentrations of compound to evaluate inhibition. Initial velocities of peptide hydrolysis at
4 increasing inhibitor concentrations were performed in triplicate and the resulting average and
5 standard deviation was fit to the Morrison equation for tight binding inhibitors (41) to obtain a K_i
6 value. The error on the K_i value is determined from standard error of fitting to the equation. The
7 K_M value used for the Morrison equation was from the Michaelis-Menten kinetic analysis with
8 the FRET peptide for M^{pro} and each mutant as determined in this study.

9 Morrison equation:

$$Y = V_o * (1 - (((Et + X + (Ki * (1 + (S/KM)))) - (((Et + X + (Ki * (1 + (S/KM))))^2 - 4 * Et * X)^{0.5}))/ (2 * Et)))$$

10 where Y is enzyme activity, X is the concentration of inhibitor, Et is the concentration of
11 enzyme, K_m is the Michaelis constant, and S is the substrate concentration.

12

13 **Production of recombinant SARS-CoV-2**

14 Recombinant SARS2 containing the M^{pro} variants of interested were generated using a
15 previously described bacterial artificial chromosome (BAC)-based reverse genetics system based
16 on the USA-WA1/2020 (WA-1) strain (accession no. MN985325), referred to as
17 rSARS2/mCherry (25, 42). To introduce the desired mutation into full length SARS-CoV-2, first
18 a plasmid containing the ORF1a which encodes Nsp5 (termed pUC57-F3) was used as a
19 template for site directed mutagenesis to introduce the Δ P168, A173V and Δ P168/A173V
20 mutations which were confirmed by Sanger sequencing. Next, the fragment containing the
21 mutations of interested were inserted into the full length rSARS2 BAC by using the MluI and
22 PacI restriction enzymes. Vero E6 cells expressing hACE2 and TMPRSS2 (Vero AT) were
23 obtained from BEI Resources (NR-54970) and maintained in DMEM with 10% FBS, 1% PSG,
24 and 10 μ g/ml puromycin. For virus rescue, the full-length BAC containing the M^{pro} mutants were
25 transfected into confluent monolayers of Vero AT cells (10^6 cells/well, 6-well plate format). At
26 24hpi, the media was changed to post-infection medium (DMEM supplemented with 2% FBS
27 and 1% PSG) and at 48hpi the cells were split into a T75 flask. After an additional 72h
28 incubation, cell culture supernatants were harvested, labeled as P0 and frozen at -80° C.
29 Monolayers of Vero AT cells (indicate the number of cells and format) were infected at low
30 multiplicity of infection (MOI 0.0001) with P0 for 48h to generate P1 stocks. Viral RNA was
31 extracted from P1 viral stocks and subjected to Illumina next generation sequencing (NGS) to
32 confirm the presence of the desired mutations within Nsp5. P1 virus stocks were titrated and
33 used for downstream antiviral and growth kinetic assays.

34

35 **Antiviral and growth kinetic assays**

36 To avoid the nirmatrelvir efflux seen in Vero E6 cells, human A549-hACE2 cells (5×10^4
37 cells/well, 96-well plate format, quadruplicates) were infected with 200 PFU/well of WT, Δ P168,
38 A173V, or Δ P168/A173V rSARS2/mCherry and incubated for 1h at 37°C in a 5% CO₂
39 incubator. After virus adsorption, cells were washed with PBS and incubated at 37°C in phenol
40 red-free post-infection media containing two-fold serial dilutions of the indicated antiviral drug
41 (nirmatrelvir, ensitrelvir, or remdesivir with a starting concentration of 25 μ M). Fluorescence
42 mCherry expression was determined at 72 hpi using a fluorescence microscope (EVOS M5000)
43 and a Synergy LX Multimode plate reader (Agilent). Fluorescence values of mCherry virus-
44 infected cells in the absence of antiviral were used to calculate 100% viral infection. Cells in the

1 absence of viral infection were used to calculate the fluorescence background. The 50%
2 inhibitory concentrations (IC₅₀) were determined with a sigmoidal dose response curve
3 (Graphpad Prism 9).

4 To determine viral growth kinetics of the WT and mutant rSARS-CoV-2, monolayers of
5 Vero E6 cells (4x10⁵ cells/well, 12-well plate format, triplicates) were infected (MOI 0.01) and
6 incubated for 1 hr at 37°C in a 5% CO₂ incubator. After virus adsorption, cells were washed with
7 PBS and incubated at 37°C in post-infection media. At each of the indicated time points (12, 24,
8 48, and 72 hpi), viral titers were determined in cell culture supernatants by standard plaque
9 assay.

10

11 **Structural modeling**

12 *Model construction:*

13 *WT:* Washington strain (*i.e.*, “original” 2019 strain; wildtype, WT) M^{pro} structure was prepared
14 for simulation from Protein Data Bank deposition 7BB2(43). In chains A and B of 7BB2,
15 Cys128 is resolved in two conformations, thus care was taken to remove the B conformation of
16 Cys128 from both chains by manual manipulation of the .pdb file and then renumbering atoms
17 with pdb-tools (44). PROPKA3 was then used to calculate protonation states of titratable
18 residues in the WT structure (45). At pH 7.4, deprotonated protonation states for all aspartate and
19 glutamate were deemed appropriate, as well as protonated states for all lysines, tyrosines,
20 arginines, and cysteines not involved in disulfide bonding. No cysteines were resolved in
21 disulfide bonding patterns (43). Using atomic positions from 7BB2 structure deposited within the
22 protein data bank, histidine residues 80 and 164 were determined to be protonated at the N δ
23 atom, whereas histidine residues 64, 163, 172, and 246 were determined to be protonated at the
24 N ϵ atom. However, upon manual investigation of M^{pro}’s mechanism as well as residue
25 arrangement in the binding cleft, we determined the protonation state of histidine 41 needed to be
26 switched from protonation on the N ϵ atom (as deposited in the PDB) to protonation on the N δ
27 atom. Per residue protonation state decisions are listed in **Table S1**. Molefacture, a tool within
28 Visual Molecular Dynamics (VMD), was then used to rotate chain A Cys145 and chain A His 41
29 such that His41’s deprotonated N ϵ was pointed to Cys145’s sulfhydryl group, *i.e.*, a
30 conformation suitable for M^{pro} catalytic function (46). This molefacture procedure was repeated
31 for chain B, to ensure both catalytic dyads began simulation in catalytically active conformation.
32 The structure was then parsed with VMD checking tools to ensure there were no chirality errors
33 or cis-peptide bonds. VMD tool psfgen was then used to construct a protein structure file (psf)
34 from the resultant pdb file. This final structure was then also used as the base structure for
35 building the A173V M^{pro} variant. Due to the fact that chain A of PDB ID 7SI9 was resolved with
36 305 residues (residues 1 to 306) but chain B was resolved with 299 residues (residues 1 to 300),
37 we constructed M^{pro} in this asymmetric way as well. All variants constructed herein were
38 identically asymmetrical, *i.e.*, all chain A’s contain 305 residues and all chain B’s contain 299
39 residues.

40

41 *A173V:* Starting from the constructed WT pdb file, VMD tool psfgen was used along with the
42 mutate command to change A173 to V173.

43

44 *Δ P168:* RoseTTAFold (47, 48) was used to construct a homology model of M^{pro} Δ P168 with
45 nirmatrelvir-bound structure PDB ID 7SI9 (19) as the template. PROPKA3.0 was again used to
46 calculate pK_a’s of all titratable residues in M^{pro}. The same protonation scheme was deemed

1 appropriate for all residues (*i.e.*, deprotonation of all aspartates/glutamates, protonation of all
2 lysines/tyrosines/cysteines/arginines) and the same histidine protonation scheme was adopted as
3 resolved from 7BB2 (with exception of His41 which was set to N δ protonation). Like in the WT
4 model construction, molefacture was used to rotate Cys145 and His41 such that His41's
5 deprotonated N ϵ was pointed to Cys145's sulfhydryl group, *i.e.*, a conformation suitable for M^{pro}
6 catalytic function (procedure done for dyads on both chains A and B). The structure was then
7 parsed with VMD checking tools to ensure there were no chirality errors or cis-peptide bonds.
8 VMD tool psfgen was then used to construct a protein structure file (psf) from the resultant pdb.
9 The resultant structure was also used as the base structure for building the Δ P168/A173V M^{pro}
10 variant.

11
12 *Δ P168/A173V*: Starting from the constructed Δ P168 M^{pro} variant structure, VMD tool psfgen
13 was used along with the mutate command to add A173V.

14
15 *Solvation and Neutralization*: VMD was used to solvate all M^{pro} variant structures in water boxes
16 of 90.7 x 97.2 x 114.3 Å³ size and neutralized with 150 mM NaCl. Total number of atoms and
17 exact system box sizes per variant can be seen in **Table S2**.

18 19 **Molecular Dynamics Simulations**

20 For all MD simulations described herein, the following force field parameters were used.
21 All atoms in all systems were described according to the CHARMM36m force field (49, 50). All
22 water molecules were described according to the TIP3P water model (51). Infinite bulk
23 conditions were modeled with periodic boundary conditions (PBC) and long-range electrostatic
24 interactions were calculated with Particle Mesh Ewald (PME, interpolation order 8, grid spacing
25 2.0). Nonbonded atom pair lists were generated for all atoms within 15.5 Å of one another.
26 Nonbonded interaction energies were calculated for all atoms within 10 Å of one another. For
27 nonbonded atom pairs beyond 12Å from one another, nonbonded interactions were assigned a
28 zero-energy contribution and not calculated. For atom pairs between 10 and 12Å from one
29 another, a switching function was used to gradually switch nonbonded terms from their
30 calculated value to zero energetic contribution. The SHAKE algorithm was applied to constrain
31 all bonds between heavy atoms and hydrogens to their equilibrium distance value as listed in
32 CHARMM36m parameter files. 1-2 and 1-3 nonbonded interactions were excluded (not
33 calculated), while electrostatic interactions of 1-4 pairs are scaled (default scaling factor 1.0) and
34 Lennard-Jones potentials were modified according to CHARMM36m parameter files. Unless
35 otherwise noted, NAMD2.14 was used to conduct all following MD simulations (52, 53). For a
36 summary of all MD simulation steps described below, see **Table S3**. All MD simulations were
37 performed with San Diego Supercomputing Network's Hopper GPU cluster.

38
39 *Minimization*: While holding catalytic dyad residues (Cys145 and His41) in position with a
40 constraint (*i.e.*, "fixed atoms"), we launched three replicas of 10,000 steps of conjugate gradient
41 and line search algorithm minimization for each M^{pro} variant. We then followed each of these
42 minimization procedures with 500 steps of dynamics at 310 K. All subsequent MD simulation
43 steps were launched from final coordinates and velocities of these 500 steps of 310 K dynamics,
44 and thus all following simulation steps were performed in triplicate.

45

1 *Heating*: Velocities from previous 500 steps at 310 K were used to launch to heating procedure
2 in which the Langevin temperature and piston temperature were gradually increased from 10K to
3 310 K in increments of 25 K with 10,080 MD steps performed at each temperature (at
4 1fs/timestep, thus 10ps of sampling per temperature). Once the system reached 310 K, an
5 additional 10,080 steps (10ps) of simulation were performed (thus 20 ps total performed at 310
6 K). During this heating procedure, catalytic dyad residues were again constrained (*i.e.*, Cys145
7 and His41 of chains A and B were held fixed) to their final position after the previous
8 minimization step.

9
10 *NpT Equilibration*: Final coordinates and velocities from heating simulations were used to
11 launch 25,200 steps (1fs/timestep, thus 252 ps) of NpT equilibration. Pressure was set to 1
12 atmosphere, and the periodic cell was allowed to be flexible during simulation (useFlexibleCell
13 set to yes) to equilibrate the cell volume. During NpT equilibration, constraint on the catalytic
14 dyad residues were removed and instead the catalytic dyad residues were restrained to their
15 positions following heating (harmonic restraint with force constant of 1 kcal/mol/Å).

16
17 *NVT Equilibration*: Final coordinates and velocities from NpT equilibration simulations were
18 used to launch 27,500,000 steps (1 fs/timestep, thus 27.5 ns) of NVT equilibration. During NVT
19 equilibration, pressure was maintained at 1 atmosphere. The box dimensions were fixed to the
20 dimensions from the final step of NpT equilibration (useFlexibleCell set to no). All restraints and
21 constraints were removed, and no new constraints/restraints were implemented during NVT
22 equilibration, thus all atoms were allowed full flexibility.

23
24 *Statistical Sampling with NAMD3.0/GPU*: Final coordinates and velocities from NVT
25 equilibration simulations were used to launch 275,000,000 steps (2 fs/timestep, thus 550 ns; note
26 the timestep change from previous methods) of statistically relevant sampling at the NVT
27 ensemble. Pressure was maintained at 1 atmosphere, and the volume was fixed at each step
28 (useFlexibleCell set to no). Due to the switch from 1 to 2 fs timestep, and the switch from
29 NAMD2.14 on CPUS to NAMD3.0 on GPU, we simulated for 550 ns to allow for 50 ns of final
30 “equilibration” if need be, before collecting results from the final 500 ns. However, after
31 performing initial analysis, we observed that all simulations appeared similarly equilibrated by
32 Root Mean Square Deviation from their starting structure (**Figure S6**), thus we deemed it
33 appropriate to incorporate all 550ns sampling per replica per M^{pro} variant. Every 2500th frame
34 was written to a dcd file for analysis, thus from 275,000,000 steps we collected 110,000 frames
35 for analysis.

36 **Computational analyses**

37 MDAnalysis tools were used for all analyses described below (54, 55). All M^{pro} trajectories were
38 stripped of water and ion atoms. Due to periodic boundary effects, chains A and B had to be split
39 and analyzed separately. Each M^{pro} trajectory was then aligned to its first frame by C α atoms to
40 cancel rotational and translational degrees of freedom.

41
42
43 *Root mean square deviation (RMSD)*: Root mean square deviation calculations were performed
44 with the MDAnalysis RMSD calculator. First, each trajectory was realigned (for each variant,
45 each chain, and each replica) according to the positions of residues 1 to 167 and 169 to 300 to
46 their position in the first frame, to ensure no biases introduced by the addition of the extra

1 residue 168 in the alignment. Then RMSD was calculated for each of these same C α atoms and
2 is plotted in **Figure S6**. To monitor trends more clearly in data, we then calculated a rolling
3 average of the RMSD over the whole data set. In **Figure S6** we have plotted both the full data
4 set, in transparent blue and brown lines, and the rolling average of the data set, in dark blue and
5 brown lines. To calculate the average RMSD trend, for each timestep we calculated the average
6 RMSD at that timepoint across all replicas and across both chains. For the average RMSDs, we
7 have again plotted the full data set, in transparent black lines, and the rolling average of average
8 RMSDs, in dark black lines.

9

10 *Root mean square fluctuation (RMSF)*: To calculate root mean square fluctuations (RMSFs) we
11 first aligned each trajectory (per variant, per replica, and residues 1-300 per chain chain)
12 according to Ca atomic positions in the starting frame. We then used the MDAnalysis RMSF tool
13 to calculate the per residue fluctuation over the course of each trajectory. For each residue, we
14 then averaged the RMSF of that residue and used the standard deviation in RMSFs per residue to
15 estimate error. To ensure that all residues were aligned when plotting RMSFs per residue, in
16 variants where residue 168 was deleted we interpolated from average RMSFs of residue 167 and
17 169.

18

19 *Hydrogen bonding analysis*: To calculate percentage of frames with a “hydrogen bond” between
20 backbone atoms of L167 and G170, for each chain and each replica, we counted all the frames
21 for which the following two requirements were satisfied: (1) the distance between L167
22 backbone oxygen and G170 backbone nitrogen were within 4Å of one another and (2) the angle
23 formed between the L167 backbone oxygen, G170 backbone hydrogen, and G170 backbone
24 nitrogen was greater than 120°. We then determined the percentage of frames that exhibited a
25 hydrogen bond at this position and averaged these percentages over all replicas and across the
26 two chains. We then used the standard deviations of these averages to estimate error in our
27 percentage calculations.

28

29 *S4 subsite penetration by M49*: To calculate the degree of S4 subsite penetration by residue M49,
30 for every frame in all simulations (*i.e.*, each variant, each replica, for both chains) we calculated
31 the distance between the center of mass of residue M49 and the center of mass of residues 165-
32 167 and 188-192. We then used the gaussian_kde (kernel density estimation with Gaussian
33 kernels) module in SciPy to estimate smooth density plots from histograms of these M49-S4
34 subsite distances.

35

36 **SARS-CoV-2 variant analyses**

37 Relative distributions of amino acid changes at the amino acid positions of interest in
38 M^{pro} were counted using the GISAID EpiCoV web server and filtered based on viral genome
39 sequences that are considered “Complete” and “High Coverage”. The frequency of each amino
40 individual amino acid and in frame deletions were divided by the total number of changes found
41 at said position to calculate the relative frequency and plotted as a heatmap using Graphpad
42 Prism 9. To generate phylogenetic trees of viral genomes containing the M^{pro} variants of interest,
43 full length viral genomes were first retrieved from the GISAID database and filtered to exclude
44 sequences with low coverage and sequences that contained obvious errors or poor coverage
45 within Nsp5 were manually removed. Viral genomes were then uploaded to the USHER and
46 placed within a phylogenetic tree of all available sequences in the GISAID database with the

1 number of samples per subtree showing sample placement set to 50. The generated phylogenetic
2 trees were visualized using Auspice.us from NextStrain (56). Metadata for the viral genomes
3 were retrieved from GISAID and overlaid on the phylogenetic tree using the Auspice.us web
4 application. Viral genomes were similarly filtered to determine the overall frequency of each
5 variant with additional filtering of separating all Omicron sequences compared to all previous
6 lineages.

8 List of Supplementary Materials

9 Fig S1 to S12

10 Table S1 to S3

12 References and Notes

- 13 1. K. Anand, J. Ziebuhr, P. Wadhvani, J. R. Mesters, R. Hilgenfeld, Coronavirus main
14 proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* **300**, 1763-
15 1767 (2003).
- 16 2. L. Zhang *et al.*, Crystal structure of SARS-CoV-2 main protease provides a basis for design
17 of improved alpha-ketoamide inhibitors. *Science* **368**, 409-412 (2020).
- 18 3. B. Boras *et al.*, Preclinical characterization of an intravenous coronavirus 3CL protease
19 inhibitor for the potential treatment of COVID19. *Nat Commun* **12**, 6055 (2021).
- 20 4. R. F. Service, A call to arms. *Science* **371**, 1092-1095 (2021).
- 21 5. C. Flexner, HIV-protease inhibitors. *N Engl J Med* **338**, 1281-1292 (1998).
- 22 6. J. Anderson, C. Schiffer, S. K. Lee, R. Swanstrom, Viral protease inhibitors. *Handbook of*
23 *Experimental Pharmacology*, 85-110 (2009).
- 24 7. A. Luttens *et al.*, Ultralarge virtual screening identifies SARS-CoV-2 main protease
25 inhibitors with broad-spectrum activity against coronaviruses. *J Am Chem Soc* **144**, 2905-
26 2920 (2022).
- 27 8. C. H. Zhang *et al.*, Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from
28 molecular sculpting of the drug perampanel guided by free energy perturbation
29 calculations. *ACS Cent Sci* **7**, 467-475 (2021).
- 30 9. J. Qiao *et al.*, SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse
31 model. *Science* **371**, 1374-1378 (2021).
- 32 10. A. D. Rathnayake *et al.*, 3C-like protease inhibitors block coronavirus replication in vitro and
33 improve survival in MERS-CoV-infected mice. *Sci Transl Med* **12**, (2020).
- 34 11. C. M. Consortium, Open science discovery of oral non-covalent SARS-CoV-2 main protease
35 inhibitor therapeutics. *BioRxiv* <https://doi.org/10.1101/2020.10.29.339317> (2022).
- 36 12. D. R. Owen *et al.*, An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment
37 of COVID-19. *Science* **374**, 1586-1593 (2021).
- 38 13. <https://www.shionogi.com/global/en/news/2022/11/e20221122.html>
- 39 14. Y. Unoh *et al.*, Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease
40 inhibitor clinical candidate for treating COVID-19. *Journal of Medicinal Chemistry* **65**,
41 6499-6512 (2022).
- 42 15. A. Telenti, E. B. Hodcroft, D. L. Robertson, The evolution and biology of SARS-CoV-2
43 variants. *Cold Spring Harbor Perspectives in Medicine* **12**, (2022).

- 1 16. S. A. Moghadasi *et al.*, Gain-of-signal assays for probing inhibition of SARS-CoV-2
2 M(pro)/3CL(pro) in living cells. *mBio* **13**, e0078422 (2022).
- 3 17. <https://www.fda.gov/media/155050/download>
- 4 18. Y. Shu, J. McCauley, GISAID: Global initiative on sharing all influenza data - from vision to
5 reality. *Euro Surveill* **22**, (2017).
- 6 19. D. W. Kneller *et al.*, Covalent narpilaprevir- and boceprevir-derived hybrid inhibitors of
7 SARS-CoV-2 main protease. *Nat Commun* **13**, 2268 (2022).
- 8 20. J. Barrila, U. Bacha, E. Freire, Long-range cooperative interactions modulate dimerization in
9 SARS 3CLpro. *Biochemistry* **45**, 14908-14916 (2006).
- 10 21. E. Heilmann *et al.*, A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main
11 protease activity and chemical inhibition. *Commun Biol* **5**, 391 (2022).
- 12 22. S. Chamakuri *et al.*, DNA-encoded chemistry technology yields expedient access to SARS-
13 CoV-2 M(pro) inhibitors. *Proc Natl Acad Sci U S A* **118**, (2021).
- 14 23. S. Legare, F. Heide, B. A. Bailey-Elkin, J. Stetefeld, Improved SARS-CoV-2 main protease
15 high-throughput screening assay using a 5-carboxyfluorescein substrate. *J Biol Chem*
16 **298**, 101739 (2022).
- 17 24. C. J. Kuo, Y. H. Chi, J. T. Hsu, P. H. Liang, Characterization of SARS main protease and
18 inhibitor assay using a fluorogenic substrate. *Biochem Biophys Res Commun* **318**, 862-
19 867 (2004).
- 20 25. K. Chiem *et al.*, Generation and characterization of recombinant SARS-CoV-2 expressing
21 reporter genes. *J Virol* **95**, (2021).
- 22 26. Y. Turakhia *et al.*, Ultrafast sample placement on existing tRees (USHER) enables real-time
23 phylogenetics for the SARS-CoV-2 pandemic. *Nat Genet* **53**, 809-816 (2021).
- 24 27. Z. Lv *et al.*, Targeting SARS-CoV-2 proteases for COVID-19 antiviral development. *Front*
25 *Chem* **9**, 819165 (2021).
- 26 28. Y. Hu *et al.*, Naturally occurring mutations of SARS-CoV-2 main protease confer drug
27 resistance to nirmatrelvir. *BioRxiv* <https://doi.org/10.1101/2022.06.28.497978> (2022).
- 28 29. Y. Zhou *et al.*, Nirmatrelvir resistant SARS-CoV-2 variants with high fitness *in vitro*.
29 *BioRxiv* <https://doi.org/10.1101/2022.06.06.494921> (2022).
- 30 30. S. Iketani *et al.*, Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. *BioRxiv*,
31 (2022).
- 32 31. D. Jochmans *et al.*, The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are
33 selected by a protease inhibitor *in vitro* and confer resistance to nirmatrelvir. *BioRxiv*
34 <https://doi.org/10.1101/2022.06.07.495116> (2022).
- 35 32. E. Heilmann, F. Costacurta, A. Volland, D. von Laer, SARS-CoV-2 3CLpro mutations
36 confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-
37 function system. *BioRxiv* <https://doi.org/10.1101/2022.07.02.495455> (2022).
- 38 33. Y. Zhao *et al.*, Structural basis for replicase polyprotein cleavage and substrate specificity of
39 main protease from SARS-CoV-2. *Proc Natl Acad Sci U S A* **119**, e2117142119 (2022).
- 40 34. https://www.japic.or.jp/mail_s/pdf/23-11-1-07.pdf
- 41 35. G. Dias Noske *et al.*, Structural basis of nirmatrelvir and ensitrelvir resistance profiles against
42 SARS-CoV-2 main protease naturally occurring polymorphisms. *BioRxiv*
43 <https://doi.org/10.1101/2022.08.31.506107> (2022).
- 44 36. R. A. Bull *et al.*, Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome
45 analysis. *Nat Commun* **11**, 6272 (2020).

- 1 37. E. Lontok *et al.*, Hepatitis C virus drug resistance-associated substitutions: State of the art
2 summary. *Hepatology* **62**, 1623-1632 (2015).
- 3 38. N. M. King, M. Prabu-Jeyabalan, E. A. Nalivaika, C. A. Schiffer, Combating susceptibility to
4 drug resistance: lessons from HIV-1 protease. *Chem Biol* **11**, 1333-1338 (2004).
- 5 39. A. Molla *et al.*, Ordered accumulation of mutations in HIV protease confers resistance to
6 ritonavir. *Nat Med* **2**, 760-766 (1996).
- 7 40. Y. Liu *et al.*, Use of a fluorescence plate reader for measuring kinetic parameters with inner
8 filter effect correction. *Analytical Biochemistry* **267**, 331-335 (1999).
- 9 41. J. F. Morrison, Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-
10 binding inhibitors. *Biochim Biophys Acta* **185**, 269-286 (1969).
- 11 42. C. Ye, L. Martinez-Sobrido, Use of a bacterial artificial chromosome to generate
12 recombinant SARS-CoV-2 expressing robust levels of reporter genes. *Microbiol Spectr*
13 **10**, e0273222 (2022).
- 14 43. E. Costanzi *et al.*, Structural and biochemical analysis of the dual inhibition of MG-132
15 against SARS-CoV-2 main protease (Mpro/3CLpro) and human cathepsin-L.
16 *International journal of Molecular Sciences* **22**, (2021).
- 17 44. J. Rodrigues, J. M. C. Teixeira, M. Trellet, A. Bonvin, pdb-tools: a swiss army knife for
18 molecular structures. *F1000Res* **7**, 1961 (2018).
- 19 45. M. H. Olsson, C. R. Sondergaard, M. Rostkowski, J. H. Jensen, PROPKA3: Consistent
20 Treatment of Internal and Surface Residues in Empirical pKa Predictions. *J Chem Theory*
21 *Comput* **7**, 525-537 (2011).
- 22 46. W. Humphrey, A. Dalke, K. Schulten, VMD: visual molecular dynamics. *Journal of*
23 *Molecular Graphics* **14**, 33-38, 27-38 (1996).
- 24 47. I. R. Humphreys *et al.*, Computed structures of core eukaryotic protein complexes. *Science*
25 **374**, eabm4805 (2021).
- 26 48. M. Baek *et al.*, Accurate prediction of protein structures and interactions using a three-track
27 neural network. *Science* **373**, 871-876 (2021).
- 28 49. J. Huang, A. D. MacKerell, Jr., CHARMM36 all-atom additive protein force field: validation
29 based on comparison to NMR data. *Journal of Computational Chemistry* **34**, 2135-2145
30 (2013).
- 31 50. J. Huang *et al.*, CHARMM36m: an improved force field for folded and intrinsically
32 disordered proteins. *Nat Methods* **14**, 71-73 (2017).
- 33 51. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, Comparison of simple potential functions
34 for simulating liquid water. *J Chem Phys* **79**, 926 (1983).
- 35 52. J. C. Phillips *et al.*, Scalable molecular dynamics with NAMD. *Journal of Computational*
36 *Chemistry* **26**, 1781-1802 (2005).
- 37 53. J. C. Phillips *et al.*, Scalable molecular dynamics on CPU and GPU architectures with
38 NAMD. *J Chem Phys* **153**, 044130 (2020).
- 39 54. N. Michaud-Agrawal, E. J. Denning, T. B. Woolf, O. Beckstein, MDAnalysis: a toolkit for
40 the analysis of molecular dynamics simulations. *Journal of Computational Chemistry* **32**,
41 2319-2327 (2011).
- 42 55. R. J. Gowers *et al.*, MDAnalysis: a python package for the rapid analysis of molecular
43 dynamics simulations. *doi:10.25080/Majora-629e541a-00e* (2019).
- 44 56. J. Hadfield *et al.*, Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* **34**,
45 4121-4123 (2018).

46

1 **Acknowledgments:** We thank several members of the Harris lab and R. Langlois for support
2 and constructive feedback. RSH is an Investigator of the Howard Hughes Medical
3 Institute, a CPRIT Scholar, and the Ewing Halsell President’s Council Distinguished
4 Chair at University of Texas Health San Antonio.

5 **Funding:**

6 National Institute of Allergy and Infectious Disease grant U19-AI171954 (RSH, REA,
7 TP, HA), and Austrian Science Fund (FWF) grant in the special call “SARS urgent
8 funding” (EH, DvL).

9 **Author contributions:**

10 Conceptualization: SAM, RSH
11 Methodology: SAM, EH, AK, CN, FLK, CY, SNM, TP
12 Investigation: SAM, EH, AK, CN, FLK, CY, SNM, FLK, FC, MAE
13 Visualization: SAM, FLK, HA
14 Funding acquisition: SAM, EH, DvL, RSH, REA, TP, LMS
15 Project administration: RSH
16 Supervision: RSH, DvL, REA, TP, LMS
17 Writing – original draft: SAM, RSH
18 Writing – review & editing: All authors

19 **Competing interests:** DvL is founder of ViraTherapeutics GmbH and serves as a scientific
20 advisor to Boehringer Ingelheim and Pharma KG. The other authors have no competing
21 interests to declare.

22 **Data and materials availability:** All data are available in the main text or the supplementary
23 materials.

24

25 **FIGURE LEGENDS**

26

27 **Fig. 1. Δ P168 confers resistance to nirmatrelvir and ensitrelvir.**

28 (A) Relative frequency of amino acid changes at P168, excluding proline (open circle), in
29 SARS2 genomes (1-July-2022, GISAID database).

30 (B) Co-crystal structures of SARS2 M^{pro} in complex with boceprevir (PDB: 6WNP), nirmatrelvir
31 (PDB: 7SI9), and ensitrelvir (PDB: 7VU6).

32 (C) Dose-response curves of WT, P168S, and Δ P168 M^{pro} variants using the live cell Src-M^{pro}-
33 Tat-fLuc assay with 4-fold serial dilution of inhibitor beginning at 10 μ M for nirmatrelvir
34 and ensitrelvir or 100 μ M for boceprevir (data are mean +/- SD of biologically
35 independent triplicate experiments).

36 (D) Relative luminescence of cells expressing Src-M^{pro}-Tat-fLuc variants in the absence of
37 inhibitor.

38 (E) Dose-response curves of nirmatrelvir and ensitrelvir against WT and Δ P168 M^{pro} in an
39 orthologous VSV-based M^{pro} *cis*-cleavage assay (data are mean +/- SD of biologically
40 independent triplicate experiments).

41

1 **Fig. 2. Variable active site residues elicit differential resistance to nirmatrelvir and**
2 **ensitrelvir.**

3 (A) Alignment of coronavirus M^{pro} amino acid sequences spanning residues 41-54 and 163-174
4 (based on SARS2 M^{pro} residue position).

5 (B) Structure of SARS2 M^{pro} and inhibitors highlighting variable residues that can be mutated
6 (PDB: 7SI9 and 7VU6 for nirmatrelvir and ensitrelvir, respectively).

7 (C) Relative frequency of amino acid changes at tested variable residues, excluding the
8 respective WT residue (open circle), in SARS2 genomes (1-July-2022, GISAID
9 database).

10 (D) Relative luminescence of cells expressing Src-M^{pro}-Tat-fLuc variants in the absence of
11 inhibitor.

12 (E-F) Dose-response curves of variants using the live cell Src-M^{pro}-Tat-fLuc assay with 4-fold
13 serial dilution of inhibitor beginning at 10 μ M (data are mean +/- SD of biologically
14 independent triplicate experiments).

15

16 **Fig. 3. Δ P168/A173V double mutant elicits synergistic selective resistance to nirmatrelvir.**

17 (A) Dose-response of Δ P168/A173V mutant vs WT using the live cell Src-M^{pro}-Tat-fLuc assay
18 with 4-fold serial dilution of inhibitor beginning at 10 μ M.

19 (B) Relative luminescence of cells expressing respective Src-M^{pro}-Tat-fLuc variants in the
20 absence of inhibitor.

21 (C) Kinetic parameters of purified M^{pro} variants *in vitro* using the Dabcyl-KTSAVLQSGFRKM-
22 E(Edans)-NH₂ FRET peptide (FP) as a substrate.

23 (D) K_i of nirmatrelvir and ensitrelvir for purified M^{pro} variants derived using the Morrison
24 equation with kinetic parameters calculated from data in panel C.

25 (E-F) Antiviral activity of nirmatrelvir, ensitrelvir, and remdesivir with the indicated
26 recombinant SARS2 viruses in A549-hACE2 cells (2-fold dilution series beginning at 25
27 μ M, data are mean +/- SD of biologically independent quadruplicate experiments).

28 (G) Representative fluorescence microscopy images of mCherry-expressing WT and
29 Δ P168/A173V SARS2 infections following dosage with the indicated concentrations of
30 nirmatrelvir.

31

32 **Fig. 4. Structural interpretation of M^{pro} Δ P168/A173V synergistic resistance to**
33 **nirmatrelvir.**

34 (A) Root-mean square fluctuations (RMSFs) calculated per residue for each simulated M^{pro}
35 variant. To maintain numbering consistency, RMSFs for deleted residues are plotted as
36 the interpolation of values from the prior residue (167) and the following residue (169).
37 Calculated RMSFs per residue were averaged over all replicas and across chains A and
38 B. Inset plots highlight increased flexibility of regions 40-70 and 180-200.

39 (B) Molecular model images demonstrating the flexibility of residues 40-70 and 180-200
40 captured in simulations of WT, Δ P168, A173V, and Δ P168/A173V. All MD frames were
41 aligned to the 7SI9 crystal structure (blue ribbons) to highlight the nirmatrelvir (carbon
42 atoms represented in yellow licorice) binding site. MD simulation frames, in crystal,

- 1 closed, and open conformations, are represented in chocolate brown, golden brown, and
2 latte brown ribbons, respectively.
- 3 (C) Histograms demonstrating the distribution of frames for which M49 penetrates the S4
4 subpocket and the distribution of frames for which M49 (and thus residues 43-53) moves
5 far above M^{pro}'s native binding groove.
- 6 (D) Molecular model images demonstrating the binding site β -hairpin structure (residues 165-
7 175) as seen in WT (blue ribbons), Δ P168 (golden brown), A173V (chocolate brown),
8 and Δ P168/A173V (latte brown) MD frames. Hydrogen bonds, or lack thereof, between
9 L167 backbone carbonyl and G170 backbone nitrogen are highlighted.
- 10 (E) Percentage of frames calculated in which the L167-G170 backbone hydrogen bond is
11 observed. Hydrogen bond requirements were established as: $<4\text{\AA}$ between L167
12 backbone carbonyl oxygen and G170 backbone nitrogen, and an angle of >120 degrees
13 between L167 backbone carbonyl oxygen, G170 backbone hydrogen, and G170
14 backbone nitrogen (see results for complete characterization). Percentages were
15 calculated and averaged per replica and per chain, and standard deviations used as error
16 estimates.

17

18 **Fig. 5. Phylogenetic analyses suggest mutual exclusivity for P132H and Δ P168.**

- 19 (A) Phylogenetic trees for viral genomes with the indicated resistance mutations (GISAID, 6-
20 December-2022). Only the Omicron lineage is displayed for M49I due to the high
21 frequency of this mutation.
- 22 (B) Branches of the phylogenetic tree from panel A showing transmission of a Delta lineage
23 isolate with Δ P168 likely from a single founder event.
- 24 (C) Frequency of M^{pro} variants in Omicron lineage compared to all previous viral lineages.
- 25 (D) Background luminescence as a proxy for protease activity of different M^{pro} variants on the
26 P132H (Omicron) background using the live cell Src-M^{pro}-Tat-fLuc assay.
- 27 (E) Dose-response curves for nirmatrelvir and ensitrelvir inhibition of M^{pro} variants on the
28 P132H (Omicron) background using the live cell Src-M^{pro}-Tat-fLuc assay.

29

30

31

1 **Table 1. Summary of nirmatrelvir and ensitrelvir resistance phenotypes of SARS2 M^{pro}**
 2 **variants tested in the live cell gain-of-signal assay.** Fold-resistance for each mutant tested was
 3 calculated based on relative IC₅₀ in the live cell gain-of-signal assay versus WT in assays ran in
 4 parallel to limit potential variability due to transfection efficiency. Frequency of variants based
 5 on sequences deposited in the GISAID database as of 10-December-2022 (7,391,988 “Pre-
 6 Omicron” sequences and 6,830,473 “Omicron-present” sequences).
 7

M ^{pro} variant	Frequency in GISAID		Nirmatrelvir		Ensitrelvir	
	Pre-Omicron	Omicron-present	IC ₅₀ nM (95% CI)	Fold-resistance (relative to WT)	IC ₅₀ nM (95% CI)	Fold-resistance (relative to WT)
WT	-	-	31.6 (26.1 to 37.7)	-	23.0 (20.4 to 25.9)	-
T45I	3.5x10 ⁻⁴	4.8x10 ⁻⁵	64.2 (46.2 to 85.7)	~2	111 (92.4 to 132)	4.1
S46F	4.1x10 ⁻⁴	1.1x10 ⁻⁴	34.5 (28.3 to 41.5)	<2	34.5 (28.3 to 41.5)	<2
E47K	1.2x10 ⁻⁴	7.6x10 ⁻⁶	27.3 (10.0 to 44.3)	<2	17.4 (12.8 to 21.8)	<2
D48Y	1.4x10 ⁻⁵	1.6x10 ⁻⁶	62.7 (44.0 to 88.9)	~2	135 (99.3 to 184)	5.0
M49I	2.5x10 ⁻⁴	2.3x10 ⁻⁵	33.5 (20.6 to 46.7)	<2	335 (197 to 664)	12.4
M49L	6x10 ⁻⁵	7.5x10 ⁻⁷	21.2 (17.1 to 25.9)	<2	436 (38 to 573)	25.4
M49T	1x10 ⁻⁵	-	11.1 (10.2 to 12.1)	<2	69.0 (63.3 to 75.2)	4.0
M49V	4.7x10 ⁻⁶	3.7x10 ⁻⁶	7.9 (7.0 to 8.9)	<2	44.5 (38.2 to 51.7)	2.6
S144A	1.3x10 ⁻⁶	6.5x10 ⁻⁷	267 (215 to 334)	12.2	395 (304 to 523)	16.9
M165I	1.2x10 ⁻⁵	4.2x10 ⁻⁶	29.9 (22.4 to 39.5)	<2	49.3 (33.3 to 67.2)	~2
P168S	5.1x10 ⁻⁵	2x10 ⁻⁵	19.9 (15.5 to 25.0)	<2	36.4 (30.1 to 43.6)	<2
ΔP168	9.5x10 ⁻⁶	1.6x10 ⁻⁷	180 (154 to 219)	5.1	157 (132 to 188)	6.8
T169I	5.1x10 ⁻⁵	9.2x10 ⁻⁶	34.0 (23.7 to 45.0)	<2	30.9 (24.1 to 38.7)	<2
V171I	5.3x10 ⁻⁵	2.8x10 ⁻⁵	21.1 (13.6 to 28.3)	<2	33.4 (26.4 to 41.2)	<2
A173V	1.8x10 ⁻⁵	1.0x10 ⁻⁵	328 (186 to 796)	11.6	29.6 (24.2 to 35.4)	<2
A173T	1.2x10 ⁻⁵	2.4x10 ⁻⁵	77.6 (104 to 132)	4.1	28.3 (24.0 to 33.1)	<2
A173S	1.1x10 ⁻⁵	1.3x10 ⁻⁶	18.6 (15.9 to 21.2)	<2	26.2 (22.3 to 30.5)	<2
ΔP168/A173V	-	-	1510 (1380 to 1660)	51	90.5 (80.9 to 102)	2.8
T45I/M49L	-	-	20.8 (16.4 to 25.6)	<2	1030 (814 to 1340)	54.5
T45I/A173V	-	-	414 (351 to 494)	20.6	79.2 (66.4 to 94.7)	4.2
D48Y/ΔP168	-	-	921 (732 to 1220)	45.9	754 (676 to 857)	39.9
M49I/ΔP168	-	-	151 (11.9 to 210)	7.5	990 (772 to 1310)	52.5
M49L/ΔP168	-	-	144 (129 to 162)	7.2	2400 (1890 to 3110)	127

8

1 **Table 2: Resistance phenotypes of M^{pro} variants using the VSV-based *cis*-cleavage system.**
 2 Fold-resistance is calculated by relative IC₅₀ versus WT in assays ran in parallel (*, asterisk
 3 indicates an estimated value due to highest drug concentration failing to restore 50% activity).
 4

M ^{pro} variant	Nirmatrelvir		Ensitrelvir	
	IC ₅₀ μM (95% CI)	Fold- resistance (relative to WT)	IC ₅₀ μM (95% CI)	Fold- resistance (relative to WT)
WT	11.2 (10.8 to 11.7)	-	12.9 (12.2 to 14.4)	-
T45I	13.0 (11.2 to 15.4)	<2	48.1 (45.9 to 50.7)	3.7
D48Y	15.7 (14.6 to 17.1)	<2	27.5 (26.0 to 28.7)	2.1
M49I	4.1 (3.8 to 4.4)	<2	>100*	>10*
M49L	6.7 (6.5 to 6.9)	<2	>100*	>10*
ΔP168	35.5 (32.2 to 47.2)	7.1	19.1 (16.9 to 20.1)	3.5
A173T	45.3 (40.0 to 55.2)	4.0	18.8 (18.3 to 19.3)	<2
A173V	82.6 (59.5 to 93.5)	7.4	10.3 (3.8 to 27.3)	<2
ΔP168/A173V	>100*	>10*	37.4 (33.2 to 43.0)	3.1
T45I/ΔP168	>100*	>10*	>100*	>10*
T45I/A173V	>100*	>10*	27.4 (24.2 to 29.6)	2.2
D48Y/ΔP168	>100*	>10*	>100*	>10*
M49I/ΔP168	33.1 (32.0 to 34.2)	3.0	>100*	>10*

5
6
7
8
9
10
11
12
13
14

1 **Table 3: Resistance phenotypes of M^{pro} variants in replication-competent SARS-CoV-2.**
2

M ^{pro} variant	Nirmatrelvir	Ensitrelvir	Remdesivir
	IC ₅₀ nM (95% CI)	IC ₅₀ nM (95% CI)	IC ₅₀ μM (95% CI)
WT	4.4 (3.4 to 5.5)	4.3 (2.9 to 5.8)	1.2 (0.59 to 2.5)
ΔP168	7.0 (4.1 to 10.2)	3.6 (2.7 to 4.4)	1.1 (0.59 to 2.0)
A173V	36.0 (29.8 to 43.0)	7.8 (6.2 to 9.5)	1.3 (0.85 to 2.1)
ΔP168/A173V	275 (161 to 465)	3.3 (2.1 to 4.8)	1.5 (0.78 to 2.9)

3

4









